Advertisements

Bronco Penamox

Quick links to important sections

Bronco Penamox

Advertisements
Advertisements

Method of action: Expectorant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Bronco Penamox

Quick Facts

Property Description
Active Ingredients Amoxicillin and Ambroxol
Form Oral dosage forms (tablets, capsules, syrup, suspension)
Pharmacological Class Beta-Lactam antibacterial agent and mucolytic agent
Common Use Managing bacterial respiratory infections associated with viscous mucus
Origin Semi-synthetic (Amoxicillin) and Synthetic (Ambroxol)

What is Bronco Penamox and What Type of Medicine Is It?

Bronco Penamox is a specialized pharmaceutical product defined as a Fixed-Dose Combination (FDC), engineered for systemic use to address bacterial infections that are complicated by the presence of excessively viscous mucus. This preparation is distinct because it simultaneously acts as both a broad-spectrum antibiotic and a mucolytic agent and expectorant, targeting two separate but related problems in the air passages. The drug is delivered orally and is classified under the Anatomical Therapeutic Chemical (ATC) Classification System for its dual actions. The ATC classification identifies the drug's role in addressing both microbial and physical respiratory burdens for managing conditions like bronchitis where concurrent treatment is necessary.

Composition of Bronco Penamox and Its Active Ingredients

The medicine's composition features two primary Active Ingredients: Amoxicillin and Ambroxol. Amoxicillin is a semi-synthetic penicillin, categorized as an aminopenicillin and beta-lactam antibacterial agent. Ambroxol is a synthetic compound derived from bromhexine, functioning as the mucolytic component, which acts to reduce the viscosity of sputum. Amoxicillin works by inhibiting the final stage of bacterial cell wall synthesis across a broad range of susceptible pathogens. The availability of Bronco Penamox in various oral forms, including syrup and suspension, highlights its positioning for use in both adults and pediatric patients.

General Therapeutic Purpose of the Dual-Action Combination

The overall purpose of Bronco Penamox is to eliminate the microbial cause of respiratory tract infections while simultaneously making the viscous mucus easier to clear. Amoxicillin provides its bactericidal activity, and Ambroxol reduces sputum viscosity through the depolymerization of mucopolysaccharide chains. Ambroxol is characterized by its ability to improve mucociliary clearance in the respiratory tract, helping the body naturally expel accumulated secretions. This synchronized approach is utilized when the clinical presentation requires both the action of a broad-spectrum antibiotic and enhanced clearance of congested air passages, such as in managing acute exacerbations of COPD complicated by infection.

Advertisements

What side effects are possible with Bronco Penamox?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Bronco Penamox, as documented in official government regulatory documents.

Adverse effects are formally classified by frequency and grouped by the System-Organ-Class (SOC) they affect, reflecting the combined safety profiles of Amoxicillin and Ambroxol.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Effects
Common Diarrhea, Nausea, Skin rash (non-urticarial), Taste disturbance.
Uncommon Vomiting, Pruritus, Urticaria, Moderate elevation of liver enzymes.
Rare/Very Rare Headache, Dizziness, Convulsions, Reversible blood disorders (e.g., leucopenia), Hepatitis, Cholestatic jaundice, Interstitial nephritis.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights the risk of several serious adverse reactions associated with the components. These include Anaphylactic Shock and Angioedema (severe allergic reactions), as well as Severe Cutaneous Adverse Reactions (SCARs) like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Restrictions are defined by regulatory authorities. The medicine is contraindicated in individuals with a history of severe immediate hypersensitivity to any penicillin or other beta-lactam antibiotics. Treatment discontinuation is required upon the first appearance of a skin rash or other signs of hypersensitivity.

Population-Specific Safety Notes are documented for patients with renal impairment, where altered drug elimination increases the risk of Amoxicillin-related toxicities (e.g., crystalluria), necessitating careful monitoring. Similarly, caution is noted regarding patients with severe hepatic impairment due to the risk of liver dysfunction.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information addresses the clinical signs and necessary actions following an overdose of Bronco Penamox.

Documented Manifestations and Serious Risks

Symptoms reported in regulatory documents often involve the gastrointestinal, renal, and central nervous systems. Overdose presentations can include vomiting, diarrhea, abdominal pain, and drowsiness. More serious outcomes officially documented include acute renal failure, which can be linked to the formation of drug crystals in the urine (crystalluria), and potentially seizures or hepatic damage.

Required Emergency Actions

Urgent medical attention is required immediately for any suspected overdose. Emergency services should be contacted if the person has difficulty breathing, collapses, has a seizure, or cannot be awakened.

Management described in official prescribing information is primarily supportive. While no specific antidote is listed, measures such as the use of activated charcoal and ensuring adequate fluid intake may be employed. In severe cases, the drug can be removed from the bloodstream using hemodialysis.

Patients with known or underlying kidney impairment are documented to be at a higher risk for adverse outcomes due to the drug's reduced clearance from the body.

Advertisements

Therapeutic Uses of Bronco Penamox

What Bronco Penamox Treats: Main Uses and Benefits


Managing Bacterial Respiratory Infections and Associated Symptoms

This medication is commonly used across conditions presenting with acute episodes involving bacterial infections of the respiratory tract, such as acute bronchitis or bacterial sinusitis. It is applied across conditions marked by the presence of a pathogen, where it assists in addressing the microbial cause of the illness. The combination of the mucolytic agent with amoxicillin contributes to a supportive environment for managing the infection, assisting with the overall burden of infection-related manifestations. This action is relevant in settings where symptoms are driven by active bacterial colonization, supporting the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.


Clearing Viscid Mucus and Relieving Cough

Bronco Penamox is relevant for easing symptoms related to airway congestion caused by the presence of thick, sticky, or purulent mucus that is difficult to expel. It is used when symptom clusters require support for enhanced clearance, like an ineffective or effortful cough. The key therapeutic benefit is the thinning of tenacious secretions, which assists with easier expectoration and contributes to improved comfort during periods of heightened symptoms, supporting patients during difficult episodes by easing distress. This dual action is considered relevant when supportive symptom management is appropriate, as it assists with maintaining functional stability when symptoms create noticeable physiological strain.

“This medication is relevant in contexts involving heightened systemic burden where both the bacterial cause of the respiratory illness and the resulting problematic secretions are present.”


Quick Fact: Supportive Management for Congestion

Property Description
Primary Domain Bacterial Respiratory Conditions
Symptom Focus Viscid Sputum, Expectoration Difficulty, Productive Cough
Key Benefit Supports easier mucus clearance and assists in addressing the microbial cause
Patient Relevance Used for acute exacerbations of chronic lung conditions
Advertisements

Eligibility and Restrictions for Use

The official regulatory eligibility for Bronco Penamox, an Amoxicillin/Ambroxol combination, is governed by constraints on both active ingredients.

Contraindicated Populations

Patients must not use this medicine if they have a known hypersensitivity to Amoxicillin, any other penicillin or beta-lactam antibiotics (like cephalosporins), or to Ambroxol. Use is also prohibited for patients diagnosed with infectious mononucleosis.

Age- and Condition-Based Restrictions

Classification Population Restriction (Regulatory Status)
Pediatric Use Not recommended or contraindicated in children under 2 years of age (Ambroxol component, regionally defined).
Organ Impairment Caution and dose adjustment are mandated in cases of severe renal impairment and severe hepatic impairment.
Reproductive Status Not recommended during the first trimester of pregnancy or while breastfeeding, as both substances are excreted in milk.

Eligibility is generally established for adults and adolescents with no contraindications, and for pediatric patients above the minimum age limit.

Advertisements

What should I know about interactions with other medicines?

Interactions Affecting Drug Levels and Clearance

Official regulatory documentation identifies several interactions that modify the plasma exposure of the Amoxicillin component. Co-administration with Probenecid is documented to inhibit the renal tubular secretion of amoxicillin, resulting in increased and prolonged blood levels of the antibiotic. For patients with severe renal impairment, accumulation of the hepatic metabolites of the Ambroxol component is an expected outcome due to reduced elimination.

Pharmacodynamic and Outcome Interactions

Interactions that alter systemic status include the effect on coagulation: concomitant use with Oral Anticoagulants may increase the prolongation of prothrombin time (INR). When taken with Allopurinol, the incidence of skin rash is increased. Furthermore, the Amoxicillin component may reduce the efficacy of Combined Oral Contraceptives.

Specific Combination Restrictions

Co-administration with Cough Suppressants (Antitussives) is generally restricted or avoided, as the mucolytic action of Ambroxol, combined with the suppressed cough reflex, carries a formal risk of bronchial secretion accumulation. Conversely, the Ambroxol component is documented to increase the concentration of other co-administered antibiotics, such as cefuroxime and erythromycin, in bronchial secretions and lung tissue. High urine concentrations of amoxicillin may result in false-positive reactions for glucose when using copper reduction tests.

Advertisements

Mechanism of Action

Blocking Bacterial Cell Wall Construction and Overcoming Resistance

Bronco Penamox functions through a dual, synergistic mechanism. The Amoxicillin component exerts its effect by acting as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), specifically the DD-transpeptidases. These enzymes are crucial for the final step of peptidoglycan cross-linking necessary to construct the bacterial cell wall.

By inhibiting PBPs, the cell wall develops a structural defect, causing the bacterial cell to lyse and die due to internal osmotic pressure. The Clavulanic Acid component targets a key bacterial defense mechanism: the beta-lactamase enzyme. It acts as a suicide inhibitor against beta-lactamases that would otherwise destroy Amoxicillin. By neutralizing these enzymes, Clavulanic Acid preserves Amoxicillin’s ability to access its PBP targets, thereby enabling the core bactericidal mechanism to proceed against bacterial strains that have developed resistance. This combined action results in a significant decrease in the population of susceptible bacterial cells.

Advertisements

Dosage and Administration Information

How Bronco Penamox is Used: Official Administration Guidelines

Bronco Penamox, a fixed-dose combination of Amoxicillin and Ambroxol, is administered exclusively via the oral route as tablets, capsules, or an oral suspension. The dosing schedules are designed to maintain a consistent therapeutic level of the Amoxicillin component.


Standard Dosage and Frequency

Adult dosing typically ranges from 750 mg to 1750 mg daily of the Amoxicillin component, divided into doses. Standard adult regimens include 500 mg every 8 hours or 875 mg every 12 hours for respiratory tract infections. The treatment is a fixed course that is typically completed for a minimum of 7 to 14 days, with specific infections requiring a minimum of 10 days of therapy to ensure bacterial eradication.


Administration Requirements

Parameter Instruction
Timing in Relation to Meals Can be taken with or without food. Taking the dose at the start of a meal may help reduce potential gastrointestinal discomfort.
Suspension Preparation The powder for oral suspension must be reconstituted with water before initial use. The liquid must be shaken well before measuring each dose with a calibrated device.
Renal Impairment Adjustment Dose reduction is required for patients with severe renal impairment (Glomerular Filtration Rate < 30 mL/min). The 875 mg dose is typically not recommended in this group.
Pediatric Dosing Basis Dosing for children weighing less than 40 kg is weight-based, often 20 to 45 mg/kg/day, divided into two or three daily doses. An upper limit of 30 mg/kg/day divided every 12 hours is specified for infants three months of age or younger.

If a dose is missed, standard procedure involves taking the dose as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bronco Penamox


Evidence for Use in Acute Exacerbations of Chronic Lung Disease

Research has explored the use of Bronco Penamox in adult patients dealing with acute episodes of chronic lung conditions like chronic bronchitis or COPD, when complicated by a bacterial infection. These studies, including Randomized Controlled Trials (RCTs), primarily focused on measuring changes in respiratory symptoms (cough and expectoration) and monitoring sputum characteristics. For the mucolytic component, evidence derived from longer observation periods examined outcomes related to the patterns related to acute exacerbation frequency. What remains uncertain is the long-term effects of the combination treatment, as follow-up durations were limited to short treatment courses in many of the combination-specific trials.

Evidence for Use in Pediatric Bronchopulmonary Infections

The combination was evaluated in studies focusing on pediatric patients (infants and children) who were diagnosed with acute lower respiratory tract infections. Researchers examined outcomes related to change in symptom status (like fever) and the percentage of children who achieved a pre-defined therapeutic status metric. However, certainty remains low for the specific fixed-dose combination, as some available research was observed in trials that used a related, but not identical, combination of antibiotics alongside the mucolytic agent.

Supportive Evidence for Other Bacterial Respiratory Conditions

Supportive evidence for conditions like bacterial sinusitis is primarily built on regulatory reviews of the two individual component drugs and smaller supportive trials. Data show patterns related to the separate functional activities of the antibiotic and mucolytic, which contributes to understanding symptom patterns when both microbial and physical burdens are present. Comparative evidence is lacking for this setting, meaning the evidence base appears to rely on a synthesis of the proven effects of the two component drugs, and certainty for the combination's specific contribution to the outcome remains low.

Evidence Gaps and Follow-up Limitations

The majority of clinical research focused on short-term symptom changes during acute episodes. Long-term effects are not fully established for the fixed-dose combination, and data for certain groups remain insufficient, including evidence concerning the use of the combination in older adults with multiple underlying health issues. Overall, while research contributes to the evidence landscape, sample sizes were modest, and subgroup findings are uncertain for many populations not included in the main trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bronco Penamox (FAQ)


Q: How quickly does Bronco Penamox start to work?

A: According to regulatory documents, the antibiotic component typically reaches its highest level in the bloodstream within one to two hours after a dose is taken. This measurement of maximum concentration in the blood is a key marker used to understand the drug's absorption profile.


Q: How long do the effects of Bronco Penamox last?

A: Official product information describes the half-life of the antibiotic component as approximately one hour for people with normal kidney function. The drug's half-life is the time it takes for half of the dose to be eliminated, which informs the recommended dosing schedule (e.g., every 8 or 12 hours) provided in the product labeling.


Q: Is there a generic version of Bronco Penamox available?

A: The availability of a generic version is determined by local regulatory bodies and the current patent status. To check for authorized generic listings in a specific region, official national drug databases, such as those maintained by a national health authority, can be consulted.


Q: Are there common side effects that usually go away?

A: Official safety information classifies the most common side effects, such as diarrhea and nausea, as typically mild. Regulatory advice typically recommends consulting a health professional if mild effects persist or worsen, but clearly states that the medicine should be discontinued immediately upon the first signs of a severe allergic reaction.


Q: Does Bronco Penamox cause tiredness or drowsiness?

A: Official regulatory documents do not list tiredness or drowsiness as a common or uncommon side effect for this combination medicine. However, rare adverse effects, including dizziness or headache, are noted in the safety profile.


Q: Is it safe to drive after taking Bronco Penamox?

A: Official regulatory information notes that rare side effects like dizziness or convulsions may affect an individual’s ability to drive or operate machinery. If an individual experiences such effects, extreme caution should be exercised regarding driving or operating machinery.


Q: Can elderly patients use Bronco Penamox?

A: Regulatory documents address the use of this medicine in older adults. Caution is advised primarily due to the higher likelihood of decreased kidney function in this population, which may affect how the medicine is cleared from the body. Because of this, a dose adjustment may be required by a healthcare provider.


Q: Is Bronco Penamox FDA-approved?

A: The regulatory status of the drug, including its official approval or authorization for marketing by a national health authority, is confirmed within official government drug databases and labeling records.


Q: Why is Bronco Penamox sometimes described as a 'pro-drug'?

A: Official regulatory documents define the components as Amoxicillin and Ambroxol. The mechanism is described as the direct inhibition of bacterial cell wall construction and the reduction of mucus thickness. The regulatory description does not use the term 'pro-drug' but focuses on the proven dual function.


Q: What is the difference between the capsule and the tablet version of Bronco Penamox?

A: Official regulatory labeling indicates that the active ingredients and their strengths are the same across different oral forms, such as tablets and capsules. Any differences are usually related to the inactive ingredients, the size of the dosage form, or specific instructions on how it must be swallowed or prepared.


Q: Can Bronco Penamox be cut in half?

A: Regulatory instructions for splitting or crushing the tablets are provided on the label. Unless a tablet form is specifically scored and splitting is formally authorized, solid dosage forms are typically intended to be swallowed whole to help ensure the intended dose is delivered.


Q: Do I need a prescription for Bronco Penamox?

A: As an antibiotic, the combination product is classified as a Prescription Only Medicine (POM) across all jurisdictions. This means its use requires a formal medical prescription.


Q: Can Bronco Penamox be taken with pain relievers like acetaminophen?

A: Official drug interaction sections do not list acetaminophen as a documented interaction requiring a specific regulatory warning. Regulatory information primarily focuses on drugs that carry a significant risk, such as oral anticoagulants or Probenecid.


Q: What happens if I stop taking Bronco Penamox suddenly?

A: Official usage guidelines strongly emphasize that the entire prescribed course must be completed, even if symptoms begin to improve quickly. Stopping the medicine prematurely may increase the risk of the original infection recurring and could potentially contribute to the development of bacteria that are resistant to the antibiotic.


Q: How is the safety of Bronco Penamox monitored after it’s released?

A: National health agencies use a system called pharmacovigilance (or post-marketing surveillance) to continuously monitor the safety of the drug after it is released to the market. This system collects and reviews adverse event reports submitted by healthcare professionals and patients to track the drug's safety profile over time.


Q: Has Bronco Penamox been recalled in any country?

A: Information regarding any product recalls or regulatory safety alerts for specific batches is tracked and published by national and international drug regulatory authorities. This information can be verified through their official databases.


Q: Can men and women take Bronco Penamox equally?

A: Regulatory guidelines for administration and dosage are the same for adult men and non-pregnant, non-breastfeeding adult women. This is because official pharmacokinetic data does not document any clinically significant differences in drug exposure between genders.


Q: Is it true that Bronco Penamox is not recommended for people with a history of heart issues?

A: The official regulatory documentation for this medicine does not list a history of heart issues, such as cardiovascular disease, as a specific contraindication. It is not mentioned as a primary warning requiring dose adjustment.


Q: Does Bronco Penamox contain gluten or lactose?

A: Official drug labeling includes a complete list of all inactive ingredients, or excipients. The official regulatory documents should be reviewed to confirm the presence or absence of specific components like gluten or lactose.


Q: Is Bronco Penamox a controlled substance?

A: This medicine is not classified as a controlled substance under the regulatory scheduling systems used by national government drug enforcement or health agencies, such as the DEA or Health Canada.


Q: Does Bronco Penamox affect blood pressure readings?

A: Official adverse reaction documents do not commonly list changes in blood pressure (either increases or decreases) among the frequently reported or uncommon side effects of this medicine.


Q: Are there known weight changes associated with taking Bronco Penamox?

A: Regulatory lists of common, uncommon, and rare side effects do not include significant changes in body weight (either gain or loss) as a documented adverse reaction.


Q: Why do official sources list so many possible side effects for Bronco Penamox?

A: The detailed safety profile in official documents is a result of regulatory reporting requirements. These requirements mandate that manufacturers list all observed adverse events from both clinical trials and post-marketing surveillance, regardless of whether a definitive link to the drug has been established.


Q: Does the time of day matter when taking Bronco Penamox?

A: Regulatory labeling does not mandate a specific time of day; the focus is on ensuring the doses are taken at equally spaced intervals to maintain steady drug levels.


Q: What are the official guidelines regarding using Bronco Penamox with alcohol?

A: Regulatory labeling typically does not list a specific interaction or contraindication with the consumption of alcohol for this combination. Official health sources typically recommend a cautious approach regarding alcohol consumption during a course of antibiotic therapy.


Q: Can people with diabetes use Bronco Penamox safely?

A: Official regulatory documents do not list diabetes as a contraindication for use. However, regulatory warnings do note that the antibiotic component may cause false-positive results when using certain copper reduction tests for urinary glucose.


Q: Is Bronco Penamox excreted through the kidneys?

A: The official pharmacokinetic data confirms that the antibiotic component is primarily eliminated from the body through the kidneys. Because of this elimination route, official warnings indicate that dose adjustments are required by a healthcare provider in cases of severe renal impairment.


Q: Does Bronco Penamox affect mental alertness?

A: Official regulatory information does not list an effect on general mental alertness. However, the rare occurrence of nervous system side effects, such as dizziness or convulsions, is noted in the safety profile.


Q: Can Bronco Penamox be taken with other cold and flu medications?

A: Regulatory documents specifically advise caution regarding co-administration with cough suppressants, or antitussives, due to the mucolytic action of Ambroxol. Other common types of cold and flu medications, such as decongestants or antihistamines, are not explicitly listed with warnings in the interaction section.


Q: How long does Bronco Penamox stay in your system?

A: Official documents describe the clearance of the drug from the body. While a specific time is not typically provided in patient materials, the pharmacokinetic data confirms that the drug is cleared over a certain period. Regulatory documents also note that co-administration with certain medicines, such as Probenecid, can prolong the period the drug stays in the blood, which is a key factor in its clearance profile.


Advertisements

How should Bronco Penamox be stored and disposed of?

How to Store and Dispose of Bronco Penamox?

Storage and disposal requirements for Bronco Penamox are defined by regulatory labeling to maintain quality and safety.

Storage Requirements

Solid forms (tablets/capsules) must be stored at Controlled Room Temperature, typically 20 C to 25 C. The product must be kept in its original container, tightly closed, and protected from moisture and light. It is strictly mandated not to freeze the medication. The medicine must be stored out of the sight and reach of children.

Stability and Handling

If the medicine is an oral suspension, the prepared liquid form has a limited in-use stability and must be discarded after 14 days, even if it requires refrigeration during that time.

Disposal Instructions

Unused or expired medication should be disposed of via community drug take-back programs. The medication must not be disposed of via wastewater (such as flushing down the toilet) or standard household trash unless specified by official local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronco Penamox found in:

A-Z Index: